GPC3-targeted PET imaging for liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new imaging agent that may help find liver cancer more precisely. It could offer a clearer picture of your cancer or check for possible recurrence after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have or are suspected of having liver cancer (hepatocellular carcinoma)
- You have not had certain systemic treatments (such as immunotherapy, chemotherapy, or targeted therapy), or you have a suspected recurrence after treatment
- Or you have been diagnosed with liver cancer and have had a type of PET scan (18F-FDG PET/CT) for staging or restaging
- You are willing and able to cooperate with the examination
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of imaging scan (called 68Ga-NYM207 PET/CT) that may help doctors better find and understand liver cancer. You would receive the scan once to see if it helps doctors plan your treatment or monitor your cancer.
This study uses a special PET/CT scan that targets a protein (GPC3) found in liver cancer cells. The goal is to see how well it can detect or track liver cancer, whether it's newly diagnosed or has been treated before.
This trial tests a new PET imaging method that uses two different tracers to find and stage liver cancer (HCC) or neuroendocrine tumors (GEP-NET) more accurately. It may help doctors decide on the best treatment for you.
This trial uses a special PET scan (68Ga-FAPI) to see how well systemic therapy is working in people with advanced liver cancer that can't be removed by surgery. The goal is to find a better way to measure treatment effectiveness.
This trial uses a special PET scan tracer (zirconium-labelled girentuximab) to see if it can find and track certain liver, bile duct, and pancreatic/intestinal neuroendocrine tumors. It may help doctors better understand your cancer and guide treatment decisions.
This trial tests if a special PET scan (PSMA PET) can better stage liver cancer that has not been treated yet and is at a moderate to advanced stage (BCLC B or C). It may help guide treatment decisions.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.